UbiVac advances its portfolio of platform therapies through collaborations, licensing and research efforts. The company continues to work with leading universities and hospitals, including Providence Health System (Portland, Oregon), Oregon Health and Science University and the Free University of Amsterdam in the Netherlands.
UbiVac has a collaboration with Johnson & Johnson Innovation to develop and test, in preclinical studies, a vaccine to intercept oral cancer. Under the terms of the agreement, UbiVac will develop new preclinical and clinical versions of its proprietary DRibble immunotherapy for use in preclinical studies of oral cancer.
UbiVac maintains an interest in increasing these partnerships with other leading universities, government and commercial entities. To express an interest, please make an initial approach by email on our Contact Us page.